Background
HIV infection, combined antiretroviral therapy (cART) and metabolic syndrome are associated to an increased cardiovascular risk (CVR). Cystatin C, a low molecular weight cysteine protease inhibitor involved in vascular extracellular matrix remodelling, is considered a novel marker of kidney function and CVR in general population. To value the role of cystatin C in HIV infected patients without chronic kidney disease treated with cART subdivided for CVR.